Breaking News, Financial News

Financial Report: Parexel 3Q

Backlog grows, but ramping up for new business leads to tighter margins

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Parexel 3Q 3Q Revenues*: $356 million (+18%) 3Q Earnings: $22.9 million (+46%) YTD Revenues*: $1.0 billion (+11%) YTD Earnings: $45.3 million (-10%) * Consolidated service revenues only Comments: Backlog at the end of the quarter was approximately $4.2 billion (+33% year-over-year). Reported backlog included gross new business wins of $1.1 billion, cancellations of $263.3 million, and a positive impact from foreign exchange rates, and other small adjustments of $44.3 million. The net book-...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters